Lexaria Bioscience Corp. (NASDAQ: LEXX) is devoting its research and product development to making drug substances more effective in the approach to treating medical conditions such as high blood pressure and, in the process, to overcoming many obstacles that may hinder their proper use by patients. “One area of Lexaria’s research has focused on pursuing U.S. Food and Drug Administration (‘FDA’) approval to begin formal, registered clinical testing of its DehydraTECH-processed cannabidiol (‘CBD’) for the treatment of hypertension under the Investigational New Drug (‘IND’) process,” a recent article reads. “Lexaria recently announced the launch of its HYPER-H21-4 randomized, double-blinded, placebo-controlled, cross-over study of DehydraTECH-CBD in relation to hypertension, with the potential for enhancing Lexaria’s ability to treat cardiovascular and other disease states beyond hypertension that are related to increased arterial stiffness. Lexaria has already completed other human studies. Last year, studies HYPER-H21-1 and HYPER-H21-2 provided evidence that DehydraTECH-CBD successfully reduced blood pressure in similarly hypertensive human volunteers, and Lexaria announced earlier this month that it had completed all data analyses of its HYPER-H21-3 study with positive safety and efficacy findings.”

To view the full article, visit https://cnw.fm/AGTTW

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.